RT @nevillesanjana: This is so cool. A CRISPR screen discovers a new synthetic lethality that is druggable. Then, a small-scale clinical tr…
The combination therapy identified here may represent a promising strategy for the approximately 50% of patients with advanced HCC who have high levels of EGFR. https://t.co/S2w4AhLrGQ
RT @FlavioMaina: Happy to share this Editorial we wrote with Célia Sequera on a Nature paper from @BernardsLabora1 and colleagues about com…
RT @FlavioMaina: Happy to share this Editorial we wrote with Célia Sequera on a Nature paper from @BernardsLabora1 and colleagues about com…
RT @FlavioMaina: Happy to share this Editorial we wrote with Célia Sequera on a Nature paper from @BernardsLabora1 and colleagues about com…
RT @FlavioMaina: Happy to share this Editorial we wrote with Célia Sequera on a Nature paper from @BernardsLabora1 and colleagues about com…
RT @FlavioMaina: Happy to share this Editorial we wrote with Célia Sequera on a Nature paper from @BernardsLabora1 and colleagues about com…
Happy to share this Editorial we wrote with Célia Sequera on a Nature paper from @BernardsLabora1 and colleagues about combinatorial receptor targeting for HCC treatment https://t.co/7szBI9juyk. Towards precision medicine in HCC 🤞🏻🤞🏻🤞🏻 https://t.co/68wjtK
RT @m0370: マジすか、しかもnature!?合成致死といえばBRCAとPARPが有名だけど、vitro実験からレンバチニブ耐性HCCはEGFR依存が起こるのでレンバチニブとEGFR阻害剤で合成致死効果があり、実際少人数のパイロット試験ではゲフィチニブと併用で有効性が見…
そういや、これってどうなったんだ?(レンバチニブ耐性HCCでのレンバチニブ+ゲフィチニブ合成致死)
"EGFR activation limits the response of liver cancer to lenvatinib" Jin H, Shi Y, Lv Y, Yua S [..] Zhou W, Zhai B, Qin W, Bernards R. Nature. 2021-07-21. https://t.co/AqLsugtUeb
RT @oncodeinstitute: Did we already tell you that the discovery of Oncode Investigators René Bernards and @LeilaAkkari1 made the cover of @…
RT @oncodeinstitute: Did we already tell you that the discovery of Oncode Investigators René Bernards and @LeilaAkkari1 made the cover of @…
RT @oncodeinstitute: Did we already tell you that the discovery of Oncode Investigators René Bernards and @LeilaAkkari1 made the cover of @…
Did we already tell you that the discovery of Oncode Investigators René Bernards and @LeilaAkkari1 made the cover of @Nature? Read more about their findings on combination therapy for liver cancer: https://t.co/8FRxB3UV18 @NKI_nl https://t.co/iYvxPlvNDG
CRISPR–Cas9 genetic screening revealed that inhibition of EGFR is synthetic lethal with lenvatinib in liver cancer. #syntheticlethality “EGFR activation limits the response of liver cancer to lenvatinib” | Nature https://t.co/erfVcV6aiH
HEPATIC: preclinical studies identified EGFR signalling as a mechanism of escape from FGFR blockade with lenvatinib; combined FGFR and EGFR inhibition (lenvatinib + gefitinib) produced partial response in 4 of 12 lenvatinib resistant patients. https://t.co
RT @m0370: マジすか、しかもnature!?合成致死といえばBRCAとPARPが有名だけど、vitro実験からレンバチニブ耐性HCCはEGFR依存が起こるのでレンバチニブとEGFR阻害剤で合成致死効果があり、実際少人数のパイロット試験ではゲフィチニブと併用で有効性が見…
RT @m0370: マジすか、しかもnature!?合成致死といえばBRCAとPARPが有名だけど、vitro実験からレンバチニブ耐性HCCはEGFR依存が起こるのでレンバチニブとEGFR阻害剤で合成致死効果があり、実際少人数のパイロット試験ではゲフィチニブと併用で有効性が見…
RT @NatRevClinOncol: EGFR is synthetic lethal with lenvatinib in HCC models because lenvatinib inh FGFR resulting in upregulation of EGFR.…
RT @m0370: マジすか、しかもnature!?合成致死といえばBRCAとPARPが有名だけど、vitro実験からレンバチニブ耐性HCCはEGFR依存が起こるのでレンバチニブとEGFR阻害剤で合成致死効果があり、実際少人数のパイロット試験ではゲフィチニブと併用で有効性が見…
RT @NatRevClinOncol: EGFR is synthetic lethal with lenvatinib in HCC models because lenvatinib inh FGFR resulting in upregulation of EGFR.…
RT @NatRevClinOncol: EGFR is synthetic lethal with lenvatinib in HCC models because lenvatinib inh FGFR resulting in upregulation of EGFR.…
RT @NatRevClinOncol: EGFR is synthetic lethal with lenvatinib in HCC models because lenvatinib inh FGFR resulting in upregulation of EGFR.…
RT @NatRevClinOncol: EGFR is synthetic lethal with lenvatinib in HCC models because lenvatinib inh FGFR resulting in upregulation of EGFR.…
はにゃ??
CRISPR-Cas9のおかげで色んな研究者が次々とgRNAライブラリを構築していくし、こういうキノーム解析が低コストで簡便にできるようになったから、ある総当たり的な研究のハードルが下がったんだろうなあ。それにかまけず細かく裏取りもしてて丁寧な論文。 https://t.co/lAr1cGnGy4
RT @m0370: マジすか、しかもnature!?合成致死といえばBRCAとPARPが有名だけど、vitro実験からレンバチニブ耐性HCCはEGFR依存が起こるのでレンバチニブとEGFR阻害剤で合成致死効果があり、実際少人数のパイロット試験ではゲフィチニブと併用で有効性が見…
RT @m0370: マジすか、しかもnature!?合成致死といえばBRCAとPARPが有名だけど、vitro実験からレンバチニブ耐性HCCはEGFR依存が起こるのでレンバチニブとEGFR阻害剤で合成致死効果があり、実際少人数のパイロット試験ではゲフィチニブと併用で有効性が見…
RT @m0370: マジすか、しかもnature!?合成致死といえばBRCAとPARPが有名だけど、vitro実験からレンバチニブ耐性HCCはEGFR依存が起こるのでレンバチニブとEGFR阻害剤で合成致死効果があり、実際少人数のパイロット試験ではゲフィチニブと併用で有効性が見…
RT @m0370: マジすか、しかもnature!?合成致死といえばBRCAとPARPが有名だけど、vitro実験からレンバチニブ耐性HCCはEGFR依存が起こるのでレンバチニブとEGFR阻害剤で合成致死効果があり、実際少人数のパイロット試験ではゲフィチニブと併用で有効性が見…
RT @NatRevClinOncol: EGFR is synthetic lethal with lenvatinib in HCC models because lenvatinib inh FGFR resulting in upregulation of EGFR.…
RT @m0370: マジすか、しかもnature!?合成致死といえばBRCAとPARPが有名だけど、vitro実験からレンバチニブ耐性HCCはEGFR依存が起こるのでレンバチニブとEGFR阻害剤で合成致死効果があり、実際少人数のパイロット試験ではゲフィチニブと併用で有効性が見…
RT @m0370: マジすか、しかもnature!?合成致死といえばBRCAとPARPが有名だけど、vitro実験からレンバチニブ耐性HCCはEGFR依存が起こるのでレンバチニブとEGFR阻害剤で合成致死効果があり、実際少人数のパイロット試験ではゲフィチニブと併用で有効性が見…
RT @m0370: マジすか、しかもnature!?合成致死といえばBRCAとPARPが有名だけど、vitro実験からレンバチニブ耐性HCCはEGFR依存が起こるのでレンバチニブとEGFR阻害剤で合成致死効果があり、実際少人数のパイロット試験ではゲフィチニブと併用で有効性が見…
RT @m0370: マジすか、しかもnature!?合成致死といえばBRCAとPARPが有名だけど、vitro実験からレンバチニブ耐性HCCはEGFR依存が起こるのでレンバチニブとEGFR阻害剤で合成致死効果があり、実際少人数のパイロット試験ではゲフィチニブと併用で有効性が見…
RT @m0370: マジすか、しかもnature!?合成致死といえばBRCAとPARPが有名だけど、vitro実験からレンバチニブ耐性HCCはEGFR依存が起こるのでレンバチニブとEGFR阻害剤で合成致死効果があり、実際少人数のパイロット試験ではゲフィチニブと併用で有効性が見…
RT @m0370: マジすか、しかもnature!?合成致死といえばBRCAとPARPが有名だけど、vitro実験からレンバチニブ耐性HCCはEGFR依存が起こるのでレンバチニブとEGFR阻害剤で合成致死効果があり、実際少人数のパイロット試験ではゲフィチニブと併用で有効性が見…
RT @m0370: マジすか、しかもnature!?合成致死といえばBRCAとPARPが有名だけど、vitro実験からレンバチニブ耐性HCCはEGFR依存が起こるのでレンバチニブとEGFR阻害剤で合成致死効果があり、実際少人数のパイロット試験ではゲフィチニブと併用で有効性が見…
RT @NatRevClinOncol: EGFR is synthetic lethal with lenvatinib in HCC models because lenvatinib inh FGFR resulting in upregulation of EGFR.…
RT @NatRevClinOncol: EGFR is synthetic lethal with lenvatinib in HCC models because lenvatinib inh FGFR resulting in upregulation of EGFR.…
RT @NatRevClinOncol: EGFR is synthetic lethal with lenvatinib in HCC models because lenvatinib inh FGFR resulting in upregulation of EGFR.…
RT @NatRevClinOncol: EGFR is synthetic lethal with lenvatinib in HCC models because lenvatinib inh FGFR resulting in upregulation of EGFR.…
RT @NatRevClinOncol: EGFR is synthetic lethal with lenvatinib in HCC models because lenvatinib inh FGFR resulting in upregulation of EGFR.…
RT @m0370: マジすか、しかもnature!?合成致死といえばBRCAとPARPが有名だけど、vitro実験からレンバチニブ耐性HCCはEGFR依存が起こるのでレンバチニブとEGFR阻害剤で合成致死効果があり、実際少人数のパイロット試験ではゲフィチニブと併用で有効性が見…
RT @NatRevClinOncol: EGFR is synthetic lethal with lenvatinib in HCC models because lenvatinib inh FGFR resulting in upregulation of EGFR.…
RT @m0370: マジすか、しかもnature!?合成致死といえばBRCAとPARPが有名だけど、vitro実験からレンバチニブ耐性HCCはEGFR依存が起こるのでレンバチニブとEGFR阻害剤で合成致死効果があり、実際少人数のパイロット試験ではゲフィチニブと併用で有効性が見…
RT @m0370: マジすか、しかもnature!?合成致死といえばBRCAとPARPが有名だけど、vitro実験からレンバチニブ耐性HCCはEGFR依存が起こるのでレンバチニブとEGFR阻害剤で合成致死効果があり、実際少人数のパイロット試験ではゲフィチニブと併用で有効性が見…
マジすか、しかもnature!?合成致死といえばBRCAとPARPが有名だけど、vitro実験からレンバチニブ耐性HCCはEGFR依存が起こるのでレンバチニブとEGFR阻害剤で合成致死効果があり、実際少人数のパイロット試験ではゲフィチニブと併用で有効性が見られたと。すごいワ… /nature https://t.co/dAOKinX6ZR
RT @NatRevClinOncol: EGFR is synthetic lethal with lenvatinib in HCC models because lenvatinib inh FGFR resulting in upregulation of EGFR.…
EGFR is synthetic lethal with lenvatinib in HCC models because lenvatinib inh FGFR resulting in upregulation of EGFR. 12 pts with advanced-stage HCC who were unresponsive to lenvatinib received lenvatinib plus gefitinib with meaningful clinical responses
EGFR activation limits the response of liver cancer to lenvatinib https://t.co/BmFykttEcr #science
元論文の抄録によればFGFR経路をレンバチニブによって抑制されると、EGFRの系に依存してHCCが生存するようになるので、これを抑制して合成致死を誘導するらしい。すでに治験でも有効性が出ているそうな。 https://t.co/BgNq9KoJhX
Nature ハイライト:2剤による攻撃:CRISPRスクリーニングによって特定された肝臓がん治療の有効性を高める1対の薬剤 | Nature | Nature Portfolio https://t.co/npmiqjE6t5
2剤による攻撃:CRISPRスクリーニングによって特定された肝臓がん治療の有効性を高める1対の薬剤 (Nature Research) https://t.co/vSNfXmoFZC
네이처 하이라이트:2개의 공격 https://t.co/yCEbSbyXlR
RT @NatureJapan: Cover Story:2剤による攻撃:CRISPRスクリーニングによって特定された肝臓がん治療の有効性を高める1対の薬剤 | Nature https://t.co/b25BHXjlDw #肝細胞がん #CRISPRスクリーニング
Cover Story:2剤による攻撃:CRISPRスクリーニングによって特定された肝臓がん治療の有効性を高める1対の薬剤 | Nature https://t.co/b25BHXjlDw #肝細胞がん #CRISPRスクリーニング
I know it's hard to keep track of all of your reagents -- but please DO IT. It's way harder to keep track of which conclusions from which papers are built on wrong assumptions. Or maybe we should just try to get the message to the journal gatekeepers. http
Another paper with ERK5 in the abstract, and it's a Nature paper -- should we have a look? (tl;dr: this paper does not suggest inhibiting ERK5 has anti-cancer potential) https://t.co/QOKO41Em0P
EGFR activation limits the response of liver cancer to lenvatinib https://t.co/m9kk9enRQj #science
RT @Caldera60373705: https://t.co/XgdyRKRrt7 Hope for patients with HCC and high EGFR levels?
@Biotech2k1 Yes these are the most satisfying targets. Maybe some research like this in blood cancers and we'll get some https://t.co/3Q6hnWYesj
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
RT @nevillesanjana: This is so cool. A CRISPR screen discovers a new synthetic lethality that is druggable. Then, a small-scale clinical tr…
RT @nevillesanjana: This is so cool. A CRISPR screen discovers a new synthetic lethality that is druggable. Then, a small-scale clinical tr…
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
RT @nevillesanjana: This is so cool. A CRISPR screen discovers a new synthetic lethality that is druggable. Then, a small-scale clinical tr…
RT @nevillesanjana: This is so cool. A CRISPR screen discovers a new synthetic lethality that is druggable. Then, a small-scale clinical tr…
EGFR activation limits the response of liver cancer to lenvatinib | Nature https://t.co/uTgEAN5Rfr
RT @nevillesanjana: This is so cool. A CRISPR screen discovers a new synthetic lethality that is druggable. Then, a small-scale clinical tr…
RT @nevillesanjana: This is so cool. A CRISPR screen discovers a new synthetic lethality that is druggable. Then, a small-scale clinical tr…
RT @nevillesanjana: This is so cool. A CRISPR screen discovers a new synthetic lethality that is druggable. Then, a small-scale clinical tr…
RT @BernardsLabora1: Today we published in Nature a powerful new drug combination for the treatment of liver cancer. We are grateful to ou…
RT @BernardsLabora1: Today we published in Nature a powerful new drug combination for the treatment of liver cancer. We are grateful to ou…
Just in @Nature by Drs. Haojie Jin & Rene Bernards Combined gefitinib and lenvatinib inhibits hepatic cancer in murine model by blocking EGFR feedback signal. Early clinical data promising. Clincal trial is ongoing. @helops79 https://t.co/bKWb7Ahk00 ht
RT @nevillesanjana: This is so cool. A CRISPR screen discovers a new synthetic lethality that is druggable. Then, a small-scale clinical tr…
RT @nevillesanjana: This is so cool. A CRISPR screen discovers a new synthetic lethality that is druggable. Then, a small-scale clinical tr…
@GenaroActin
📄 @Nature | A group pf scientists show that EGFR activation limits the response of #liver cancer to #lenvatinib! 🙌 Read more 👇 https://t.co/HpmXy03y8J https://t.co/cIICtwXeKp
RT @mvicaracal: Online at @nature: EGFR activation limits the response of liver cancer to lenvatinib by Rene Bernards and colleagues #cance…
RT @nevillesanjana: This is so cool. A CRISPR screen discovers a new synthetic lethality that is druggable. Then, a small-scale clinical tr…
RT @pdhsu: CRISPR screens identify liver cancer synthetic lethality -> combo clinical trial identifies “a promising strategy for the approx…
#Kinome焦点化CRISPRスクリーン で、#HCC の #レンバチニブ 不奏効性の原因を同定。#EGFR 活性化による、NCT04642547初期結果が #ゲフィチニブ 併用の有望性をみせている、と:NKI。 https://t.co/ISgEfgUPHm
RT @Caldera60373705: https://t.co/XgdyRKRrt7 Hope for patients with HCC and high EGFR levels?
oh dang!
RT @pdhsu: CRISPR screens identify liver cancer synthetic lethality -> combo clinical trial identifies “a promising strategy for the approx…
RT @BernardsLabora1: Today we published in Nature a powerful new drug combination for the treatment of liver cancer. We are grateful to ou…
RT @nevillesanjana: This is so cool. A CRISPR screen discovers a new synthetic lethality that is druggable. Then, a small-scale clinical tr…
RT @nevillesanjana: This is so cool. A CRISPR screen discovers a new synthetic lethality that is druggable. Then, a small-scale clinical tr…
Congrats Haojie and the other authors for this very elegant story that our lab is proud to have helped on! @NKI_nl @oncodeinstitute